Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.59 |
| ▸ | DRD2 | P14416 | 15/20 | 0.59 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191945 | 0.92 | DRD3 (0.58) | DRD3KCNH2DRD2HRH1CHRM2 | |
| SCHEMBL4706365 | 0.91 | DRD3 (0.57) | DRD3KCNH2DRD2HRH1CHRM2 | |
| SCHEMBL4705218 | 0.88 | DRD3 (0.54) | DRD3KCNH2DRD2HRH1CHRM2 | |
| SCHEMBL4387104 | 0.87 | DRD3 (0.59) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL4703079 | 0.83 | DRD3 (0.59) | DRD3KCNH2DRD2 | |
| SCHEMBL4702422 | 0.82 | DRD3 (0.47) | DRD3KCNH2DRD2 | |
| SCHEMBL4386792 | 0.81 | DRD3 (0.63) | DRD3KCNH2DRD2HRH1CHRM1 | |
| SCHEMBL4379086 | 0.81 | DRD3 (0.52) | DRD3KCNH2DRD2HRH1CHRM2 | |
| SCHEMBL4395670 | 0.81 | DRD3 (0.56) | DRD3KCNH2DRD2HRH1CHRM2 | |
| Hydrochloric Acid SCHEMBL7200726 | 0.80 | DRD3 (0.51) | DRD3KCNH2DRD2HRH1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594861-B1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-06-18 | — | — | EP | disclosed |
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1594861-A1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | Abbott GmbH & Co. KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069830-A1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | DRD3, SLC6A3, ADORA3 | DRD3 1/4885KCNH2 887/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.